Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

GPCR

Structure Therapeutics Inc ADR

Jan 14 • 04:00PM ET

84.33

+6.41 8.23 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMY GILD BIIB AMGN MRNA NBIX NKTR INCY

| Held by: IBB SBIO FFSM EWX LRNZ OZEM ONEQ FDG FMED GXC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.65	Insider Own	2.25%	Shs Outstand	70.64M	Perf Week	27.29%
Market Cap	5.96B	Forward P/E	-	EPS next Y	-1.40	Insider Trans	0.00%	Shs Float	69.05M	Perf Month	25.75%
Enterprise Value	5.17B	PEG	-	EPS next Q	-0.38	Inst Own	97.80%	Short Float	8.75%	Perf Quarter	179.89%
Income	-210.92M	P/S	-	EPS this Y	-74.45%	Inst Trans	-0.82%	Short Ratio	3.95	Perf Half Y	330.26%
Sales	0.00M	P/B	6.65	EPS next Y	-3.03%	ROA	-23.90%	Short Interest	6.04M	Perf YTD	21.25%
Book/sh	12.69	P/C	7.46	EPS next 5Y	-	ROE	-25.31%	52W High	94.90 -11.14%	Perf Year	235.17%
Cash/sh	11.31	P/FCF	-	EPS past 3/5Y	-24.81% -51.75%	ROIC	-27.24%	52W Low	13.22 537.90%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.18% 6.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-64.91%	Oper. Margin	-	ATR (14)	5.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	76.35	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.15	EPS Q/Q	-87.88%	SMA20	24.57%	Beta	-2.15	Target Price	104.62
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	63.24%	Rel Volume	1.16	Prev Close	77.92
Employees	163	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	186.06%	Avg Volume	1.53M	Price	84.33
IPO	Feb 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.27% -	Trades		Volume	1,778,864	Change	8.23%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Initiated	Citigroup	Buy	$60
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy	$50
Dec-04-24	Initiated	H.C. Wainwright	Buy	$80
Sep-23-24	Initiated	Morgan Stanley	Overweight	$118
May-21-24	Initiated	JP Morgan	Overweight	$65
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Show Previous Ratings

Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-11-26 04:05PM	Can This Stock Double Again in 2026? (Motley Fool)
Jan-09-26 11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
Jan-08-26 09:12AM	H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 (Insider Monkey)
10:37AM	Loading…
Jan-05-26 10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks) -7.85%
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks) +12.71%
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)
Dec-17-25 08:30AM	Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-15-25 10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-12-25 10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs (GlobeNewswire)
10:23AM	Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? (Zacks)
08:10AM	Loading…
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
Dec-09-25 11:15PM	Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants (GlobeNewswire)
02:23PM	Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial (Insider Monkey)
11:15AM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-08-25 08:15PM	Why Structure Therapeutics Stock Doubled and Then Some on Monday (Motley Fool) +102.49%
04:15PM	Structure Therapeutics Soars; CEO Says It Could Have 'Best In Class' Weight-Loss Drug (Investor's Business Daily)
04:01PM	Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants (GlobeNewswire)
12:46PM	Obesity Biotechs' Gains Hit Shares of Eli Lilly, Novo Nordisk (Barrons.com)
10:36AM	Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill (The Wall Street Journal)
09:12AM	Structure details positive trial data for a weight-loss pill, and the stock rockets (MarketWatch)
08:00AM	Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 06:20PM	Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 (GlobeNewswire)
10:14PM	Loading…
Nov-16-25 10:14PM	BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts (Insider Monkey)
Nov-06-25 04:01PM	Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Oct-30-25 02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com) +8.96%
Oct-24-25 11:39AM	NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? (Zacks)
Sep-21-25 09:23AM	Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data (Insider Monkey)
Sep-12-25 08:15AM	This Under-the-Radar Healthcare Stock Could Soar in 2026 (Motley Fool)
Sep-02-25 08:30AM	Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-19-25 04:05PM	Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill (Investor's Business Daily) -5.81%
Aug-11-25 08:22PM	Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671 (Insider Monkey) +7.36% +7.02%
Aug-07-25 04:20PM	Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying (Investor's Business Daily)
09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
09:01AM	Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. (Investor's Business Daily)
Aug-06-25 04:01PM	Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jun-24-25 05:42PM	Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT (Insider Monkey)
Jun-20-25 07:30PM	Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 (GlobeNewswire)
May-29-25 04:05PM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
May-08-25 04:05PM	Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Apr-25-25 04:31PM	Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey)
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks) +6.16%
Apr-18-25 11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-15-25 10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +19.18%
Mar-24-25 07:21PM	Structure Therapeutics CEO on latest GLP-1 developments (CNBC TV)
Mar-20-25 09:28AM	Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate (SeekingAlpha)
Mar-03-25 04:20PM	AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. (Investor's Business Daily) -5.94%
Feb-27-25 04:05PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire) +14.79%
Feb-14-25 07:56AM	Why Structure Therapeutics Stock Was Stumbling This Week (Motley Fool)
Jan-30-25 08:30AM	Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences (GlobeNewswire)
Dec-18-24 10:25AM	Merck Licenses a Weight-Loss Pill. Its Bad News for Obesity Biotechs. (Barrons.com) -11.37%
Dec-17-24 04:01PM	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity (GlobeNewswire)
Dec-16-24 01:33PM	Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-27-24 10:15AM	Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-22-24 07:45AM	Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +11.00%
Nov-15-24 08:30AM	Structure Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -9.34%
Nov-13-24 04:05PM	Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
04:01PM	Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity (GlobeNewswire)
Oct-31-24 08:30AM	Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024 (GlobeNewswire) +8.69%
Oct-24-24 07:58PM	GPCR drugmaker Septerna amasses $288M in IPO (BioPharma Dive)
Oct-16-24 08:45AM	Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes (Insider Monkey) +7.41%
Oct-09-24 09:55AM	Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? (Zacks)
Oct-04-24 08:00AM	As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer (Investor's Business Daily)
Sep-29-24 02:05AM	Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? (Insider Monkey)
Sep-20-24 01:17PM	High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill (The Wall Street Journal) +8.18%
Sep-17-24 04:05PM	Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer (GlobeNewswire)
Sep-05-24 01:07AM	Structure Therapeutics Inc. (GPCR): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 04:05PM	Structure Therapeutics Appoints Angus C. Russell to Board of Directors (GlobeNewswire)
Aug-26-24 04:05PM	Structure Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 02:00PM	3 Promising Biotech Stocks for the Long-Term: August 2024 (InvestorPlace)
Aug-12-24 04:08PM	Dont Forget This Start-Ups Weight-Loss Pill, Analyst Says (Barrons.com)
Aug-08-24 08:18PM	Why Are Hedge Funds Bullish on Structure Therapeutics Inc. (GPCR) Now? (Insider Monkey)
04:05PM	Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Jul-30-24 03:07PM	3 Biotech Stocks That Could Make Your Summer Unforgettable (InvestorPlace) -8.75%
Jul-24-24 08:55AM	What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings? (Zacks)
Jul-17-24 10:47AM	Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? (Benzinga) -14.15%
Jul-12-24 06:08AM	The 3 Most Undervalued Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
Jun-17-24 09:53AM	Could Structure Therapeutics Become the Next Novo Nordisk? (Motley Fool)
Jun-11-24 07:31PM	Structure Therapeutics CEO on GLP drugs (CNBC TV) -5.42%
09:59AM	Structure Therapeutics (GPCR) Rallying on Obesity Drug Data (Zacks)
04:57AM	Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? (Motley Fool)
Jun-09-24 07:30AM	Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy? (Motley Fool)
Jun-07-24 04:05PM	Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
05:00AM	Ozempic competitors, psychedelic stocks, and Moderna after COVID: Pharma news roundup (Quartz)
Jun-05-24 07:53PM	Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering (GlobeNewswire)
Jun-04-24 11:59AM	Qiming's Nisa Leung Made the 2024 Forbes Midas List (PR Newswire)
06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your FINVIZ experience